More tools:Markets·Screener·Research·Chat

Replimune Group, Inc. (REPL) Financial Statements

Replimune Group, Inc.
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00L8Z22S0
XNAS · usd
14.75▼ 0.02 (-0.14%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close14.77
Day's Range14.61 – 14.99
52-Week Range1.50 – 16.33
Volume1.5M
Avg Volume6.0M
Share Statistics
Shares Outstanding
Employees479
ExchangeXNAS
Listed2018-07-20
Share count as of August 11, 2026
Loading Income Statement…
Key questions about Replimune Group, Inc. (REPL)
What is Replimune Group, Inc.'s Market Cap?
Replimune Group, Inc.'s Market Cap is $1.4B, based on as-reported figures from SEC (XBRL) filings.
What is Replimune Group, Inc.'s Enterprise Value?
Replimune Group, Inc.'s Enterprise Value is $1.3B, based on as-reported figures from SEC (XBRL) filings.
What is Replimune Group, Inc.'s EV / EBITDA?
Replimune Group, Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Replimune Group, Inc.'s Net Income (TTM)?
Replimune Group, Inc.'s Net Income (TTM) is -$297.0M, based on as-reported figures from SEC (XBRL) filings.
What is Replimune Group, Inc.'s EBITDA?
Replimune Group, Inc.'s EBITDA is -$294.3M, based on as-reported figures from SEC (XBRL) filings.
What is Replimune Group, Inc.'s Diluted EPS (TTM)?
Replimune Group, Inc.'s Diluted EPS (TTM) is -3.15, based on as-reported figures from SEC (XBRL) filings.
What is Replimune Group, Inc.'s Net Debt?
Replimune Group, Inc.'s Net Debt is -$86.6M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
Loss from operations
Other income (expense):
Research and development incentives
Investment income
Interest expense on finance lease liability
Interest expense on debt obligations
Other (expense) income, net
Total other (expense) income, net
Net loss
Net loss per common share, basic (in dollars per share)
Net loss per common share, diluted (in dollars per share)